Approval · Notice of Compliance 27831 · 2022
CYRAMZA: Notice of Compliance 27831
Issued March 25, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 27831
- Date
- March 25, 2022
- Company
- Eli Lilly Canada IncToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Product monograph update
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| CYRAMZA | Not yet assigned | — |
Medicinal ingredients
- RAMUCIRUMAB 10 MG per ML